Tumor-derived amyloid-β drives TREM2+ macrophages immunosuppression in cholangiocarcinoma
International Immunopharmacology · 2026-12 · 191 · 117548
DOI: 10.1016/j.intimp.2026.117548 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-12. Verfasst von Xianying Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hepato-Biliary-Pancreatic Surgery of Jining Medical Research Academy, Hepatobiliary Surgery Department, Jining First People's Hospital, …. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Shandong Province Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cholangiocarcinoma (CCA) is an aggressive malignancy with limited therapeutic options. In this study, we explored the role of TREM2+ tumor-associated macrophages (TAMs) in modulating the immune microenvironment and their impact on anti-PD-1 therapy. Using single-cell RNA sequencing data and immunohistochemical analysis, we identified a significant upregulation of TREM2 in TAMs in human CCA, correlating with decreased CD8+ T cell infiltration and poor prognosis. TREM2 deficiency in a mouse model of CCA led to a reprogramming of TAMs to a pro-inflammatory phenotype, with a marked increase in CD86+ macrophages and a significant reduction in CD206+ macrophages. This phenotypic shift enhanced the recruitment and activity of CD8+ T cells, driving a potent pro-inflammatory immune response. Additionally, we uncovered that Aβ produced by CCA cells contributes to TAM polarization through TREM2/PI3K/AKT1 signaling pathway. Blocking Aβ signaling further augmented TAM reprogramming and CD8+ T cell infiltration. The combination of TREM2 deletion and Aβ inhibition significantly enhanced the efficacy of anti-PD-1 therapy, resulting in reduced tumor growth, increased survival, and improved overall therapeutic outcomes in both subcutaneous and hydrodynamic tail vein CCA models. These findings suggest that targeting TREM2 and Aβ in conjunction with anti-PD-1 immunotherapy holds promise as a novel therapeutic strategy for CCA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Hepato-Biliary-Pancreatic Surgery of Jining Medical Research Academy, Hepatobiliary Surgery Department, Jining First People's Hospital, Shandong First Medical University, Jining, 272000, China; Clinical Med…
- Institute of Hepato-Biliary-Pancreatic Surgery of Jining Medical Research Academy, Hepatobiliary Surgery Department, Jining First People's Hospital, Shandong First Medical University, Jining, 272000, China.
- Clinical Medical Laboratory Center, Jining First People's Hospital, Shandong First Medical University, Jining, 272000, China.
- Clinical Medical Laboratory Center, Jining First People's Hospital, Shandong First Medical University, Jining, 272000, China. Electronic address: jnmclqb@mail.jnmc.edu.cn.
- Clinical Medical Laboratory Center, Jining First People's Hospital, Shandong First Medical University, Jining, 272000, China; College of Integrated Chinese and Western Medicine, Jining Medical University, Jining, Shando…
- Institute of Hepato-Biliary-Pancreatic Surgery of Jining Medical Research Academy, Hepatobiliary Surgery Department, Jining First People's Hospital, Shandong First Medical University, Jining, 272000, China. Electronic a…
Förderung
- Shandong Province Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Li, X., Qian, R., Li, Y., Xu, X., Luo, Z., Lin, H., Zhu, G., Wang, G., Gao, Y., Liu, C., Liu, F., Lin, Y., Zhang, Y., Tian, X., Liu, Q., Jiang, S., & Ma, C. (2026). Tumor-derived amyloid-β drives TREM2+ macrophages immunosuppression in cholangiocarcinoma. International Immunopharmacology, 191, 117548. https://doi.org/10.1016/j.intimp.2026.117548
Vancouver
Li X, Qian R, Li Y, Xu X, Luo Z, Lin H, et al. Tumor-derived amyloid-β drives TREM2+ macrophages immunosuppression in cholangiocarcinoma. International Immunopharmacology. 2026;191:117548. doi:10.1016/j.intimp.2026.117548
BibTeX
@article{Li2026,
author = {Li, Xianying and Qian, Ruikun and Li, Yichun and Xu, Xiangsu and Luo, Zheng and Lin, Huapeng and Zhu, Guangyong and Wang, Guobin and Gao, Yukang and Liu, Chenqiao and Liu, Fen and Lin, Yang and Zhang, Yiming and Tian, Xinchen and Liu, Qingbin and Jiang, Shulong and Ma, Changlin},
title = {Tumor-derived amyloid-β drives TREM2+ macrophages immunosuppression in cholangiocarcinoma},
journal = {International Immunopharmacology},
year = {2026},
volume = {191},
pages = {117548},
doi = {10.1016/j.intimp.2026.117548}
}
EUVIMED